Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel Free PHXM Stock Alerts

PHAXIAM Therapeutics (PHXM) Competitors

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 10/13/2026
Compare

PHXM vs. VERU, IXHL, FLNA, PYRGF, and AGFY

Should you buy PHAXIAM Therapeutics stock or one of its competitors? PHAXIAM Therapeutics's main competitors and comparable companies include Veru (VERU), Incannex Healthcare (IXHL), Cassava Sciences (FLNA), PyroGenesis Canada (PYRGF), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PHAXIAM Therapeutics compare to Veru?

Veru (NASDAQ:VERU) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

PHAXIAM Therapeutics has lower revenue, but higher earnings than Veru.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$16.89M2.21-$22.73M-$0.69N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

PHAXIAM Therapeutics' return on equity of 0.00% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
VeruN/A -47.58% -35.83%
PHAXIAM Therapeutics N/A N/A N/A

In the previous week, Veru had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Veru and 0 mentions for PHAXIAM Therapeutics. Veru's average media sentiment score of 0.93 beat PHAXIAM Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company Overall Sentiment
Veru Positive
PHAXIAM Therapeutics Neutral

Veru has a beta of -1.21, meaning that its stock price is 221% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Veru presently has a consensus price target of $24.50, suggesting a potential upside of 1,018.72%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

47.2% of Veru shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Veru beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 518.56%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, equities research analysts clearly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PHAXIAM Therapeutics has lower revenue, but higher earnings than Incannex Healthcare.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K405.78-$19.30M-$1.69N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

Incannex Healthcare has a beta of 6.97, meaning that its share price is 597% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

In the previous week, Incannex Healthcare had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Incannex Healthcare and 0 mentions for PHAXIAM Therapeutics. Incannex Healthcare's average media sentiment score of 0.43 beat PHAXIAM Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Incannex Healthcare Neutral
PHAXIAM Therapeutics Neutral

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -25.62% -24.46%
PHAXIAM Therapeutics N/A N/A N/A

Summary

Incannex Healthcare beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 572.59%. Given Cassava Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cassava Sciences is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Cassava Sciences had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Cassava Sciences and 0 mentions for PHAXIAM Therapeutics. Cassava Sciences' average media sentiment score of 0.91 beat PHAXIAM Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cassava Sciences Positive
PHAXIAM Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$0.87N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

Cassava Sciences has a beta of -0.65, suggesting that its stock price is 165% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

PHAXIAM Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -58.78% -36.74%
PHAXIAM Therapeutics N/A N/A N/A

Summary

Cassava Sciences beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

In the previous week, PyroGenesis Canada's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company Overall Sentiment
PyroGenesis Canada Neutral
PHAXIAM Therapeutics Neutral

PHAXIAM Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada-115.14% N/A -60.81%
PHAXIAM Therapeutics N/A N/A N/A

PyroGenesis Canada has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PHAXIAM Therapeutics has lower revenue, but higher earnings than PyroGenesis Canada.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada$9.14M4.24-$21.12M-$0.04N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

Summary

PHAXIAM Therapeutics beats PyroGenesis Canada on 5 of the 7 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Agrify?

Agrify (NASDAQ:AGFY) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

PHAXIAM Therapeutics has lower revenue, but higher earnings than Agrify.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agrify$12.26M3.14-$41.75M-$22.65N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

In the previous week, Agrify's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company Overall Sentiment
Agrify Neutral
PHAXIAM Therapeutics Neutral

PHAXIAM Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. PHAXIAM Therapeutics' return on equity of 0.00% beat Agrify's return on equity.

Company Net Margins Return on Equity Return on Assets
Agrify-424.11% -185.90% -72.67%
PHAXIAM Therapeutics N/A N/A N/A

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

6.0% of Agrify shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 2.2% of Agrify shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Agrify and PHAXIAM Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHXM vs. The Competition

Export
MetricPHAXIAM TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10.58M$12.42B$7.27B$12.97B
Dividend YieldN/A2.63%2.51%22.89%
P/E RatioN/A807.81275.4025.37
Price / SalesN/A748.45562.2978.82
Price / CashN/A86.6577.1653.04
Price / Book0.399.2110.555.95
Net Income-$240K$2.84B$3.50B$380.75M
7 Day PerformanceN/A-4.00%-3.92%-3.96%
1 Month PerformanceN/A-8.07%-8.30%-6.81%
1 Year PerformanceN/A-5.86%2.35%-4.58%

PHAXIAM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat		N/AN/A$10.58MN/AN/A49
VERU
Veru
3.2031 of 5 stars		$2.46
-0.4%		$24.50
+895.9%		-47.1%$41.94MN/AN/A230
IXHL
Incannex Healthcare
2.8823 of 5 stars		$3.17
-0.2%		$18.00
+468.7%		-76.2%$39.71MN/AN/A12
FLNA
Cassava Sciences
3.4934 of 5 stars		$0.82
-6.3%		$5.00
+509.7%		-81.9%$39.62MN/AN/A30
PYRGF
PyroGenesis Canada
N/A$0.17
-5.1%		N/A-14.5%$39.21M$9.14MN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...
Crypto 101 Media | Sponsoredtc pixel
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...
Paradigm Press | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel